180 Life Sciences 

180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q4 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Company Granted Extension Until July 31, 2021, to Regain Compliance Company Granted Extension Until July 31, 2021, to Regain Compliance

180 Life Sciences Files Plan with Nasdaq Related to Delayed Quarterly Report on Form 10-Q and Form 10-K

MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has appointed Pamela Marrone, PhD, and Frank Knuettel II, MBA, to its Board of Directors (“Board”) effective upon the earlier of (a) the business day following the filing of the 2020 Form 10-K Annual Report; and (b) June 28, 2021. The Board also changed the effective dates of the appointments of Russell T. Ray, MBA and Teresa DeLuca MD, MBA as members of the Board, as previously announced on May 27, 2021, to the same effective date as the appointments of Dr. Marrone and Mr. Knuettel.

180 Life Sciences Corp. Announces the Appointment of Pamela Marrone, PhD and Frank Knuettel II, MBA to Board of Directors

Management to Present Thursday June 10th Management to Present Thursday June 10th

180 Life Sciences Corp. to Present at LD Micro Invitational XI

MENLO PARK, Calif., May 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has appointed Russell T. Ray, MBA and Teresa DeLuca MD, MBA to its Board of Directors (“Board”) effective June 15, 2021.

180 Life Sciences Corp. Announces the Appointment of Russell T. Ray, MBA and Teresa DeLuca MD, MBA to Board of Directors

MENLO PARK, Calif., May 21, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, announced today that it received an expected letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because it has not yet filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 (the “Q1 2021 Form 10-Q”) with the Securities and Exchange Commission (the “SEC”). The Nasdaq notification letter has no immediate effect on the listing or trading of the Company's common stock on the Nasdaq Capital Market.

180 Life Sciences Corp. Receives Expected Notification From Nasdaq Related To Delayed Quarterly Report on Form 10-Q

MENLO PARK, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, announced today that it received an expected letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because it has not yet filed its Annual Report on Form 10-K for the year ended December 31, 2020 (the “2020 Form 10-K”) with the Securities and Exchange Commission (the “SEC”). The Nasdaq notification letter has no immediate effect on the listing or trading of the Company's common stock on the Nasdaq Capital Market.

180 Life Sciences Corp. Receives Expected Notification From Nasdaq Related To Delayed Annual Report on Form 10-K

Citius Pharmaceuticals

Jaguar Health

Ocugen, Inc.

Savara

Timber Pharmaceuticals

Zosano Pharma

So, which biotech penny stocks, popular with the Reddit set, offer such opportunity? Consider these seven as ones with potential to live up to online enthusiasm.

7 Reddit Penny Stocks to Buy for a Biotech Boom

Company actively pursuing Collagen VI pathway identified in peer-reviewed publication Company actively pursuing Collagen VI pathway identified in peer-reviewed publication

180 Life Sciences Corp. Congratulates Dr. Lynn Williams on International Dupuytren Award 2021

The stock price of 180 Life Sciences Corp (NASDAQ: ATNF) increased by over 30% during intraday trading. This is why it happened.

ATNF Stock: Over 30% Increase Intraday Explanation

Celcuity

180 Life Sciences Corp (NASDAQ: ATNF) shares are trading higher following insider buying from Marc Feldmann, a director on the company's board, and Jonathan Rothbard, the company's chief scientific officer. 180 Life Sciences is a clinical-stage biotechnology company.

What's Happening With ATNF Stock And CELC Stock?

Ikena Oncology

Evelo Biosciences Inc

Ikena Oncology, Inc. (NASDAQ: IKNA), 180 Life Sciences Corp. (NASDAQ: ATNF) and Evelo Biosciences, Inc. (NASDAQ: EVLO) are among the major biopharma movers of Monday. Ikena Oncology Gains On Fund Buying: Ikena Oncology, which listed its shares on the Nasdaq on March 26 following an initial public offering of 7.8125 million shares at $16 apiece, disclosed in a 13G filing, Citadel Advisors beneficially owned about 2,053,068 shares or a 6.6% stake in the company.

Why Ikena Oncology, Evelo Biosciences And 180 Life Sciences Are Rallying Today

Bonanza Creek Energy

Discovery Communications

Riot Blockchain

SNDL Inc.

HighPoint Resources

Ontrak

Reddit stocks continue to have the public's attention. These 7 could be the next short squeeze targets based on technical signs.

DISCB and 6 Other Reddit Stocks Waiting for a Short Squeeze

180 Life Sciences, a clinical stage research company, went public last November. The company brings together six scientists famous for their work in anti-inflammatory research.

180 Life Sciences Continues Uptrend With Cannabinoid And Anti-Inflammatory Research

180 Life Sciences Corp. (NASDAQ: ATNF) shares rallied Friday, and there was no company evident news to explain the rise in shares. The stock closed up 18.5% at $6.96.

180 Life Science Rallies 18%: Technical Levels To Watch

ATNF stock is soaring today, as investors digest a recent intriguing podcast the company released highlighting its long-term plans. The post ATNF Stock: Why 180 Life Sciences Is Soaring Higher Today appeared first on InvestorPlace.

ATNF Stock: Why 180 Life Sciences Is Soaring Higher Today

The stock price of 180 Life Sciences Corp (NASDAQ: ATNF) increased by over 50% pre-market. This is why it happened.

ATNF Stock Price Increased Over 50% Pre-Market: Why It Happened

NEW YORK, March 26, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – 180 Life Sciences Corp. (NASDAQ: ATNF) announces the availability of a broadcast titled, “Controlling Inflammation to Stop Disease.”

180 Life Sciences Corp. (NASDAQ: ATNF) Recognized R&D Pioneers in Anti-Inflammatory Therapeutics

NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — 180 Life Sciences Corp. (NASDAQ: ATNF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.

180 Life Sciences Corp. (NASDAQ: ATNF) in Hot Pursuit of New Anti-Inflammatory Blockbusters

Marathon Digital Holdings

TherapeuticsMD

Zomedica

Retail investors over on Reddit Penny Stocks are showing interest in quite a few interesting players today that investors will want to note. The post 7 Reddit Penny Stocks Seeing the Most Chatter Today appeared first on InvestorPlace.

7 Reddit Penny Stocks Seeing the Most Chatter Today

MENLO PARK, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that the Company  will present at the  Inaugural Emerging Growth Virtual Conference,  presented by M Vest LLC and Maxim Group LLC. The conference will take place on March 17 – 18, 2021 from 9:00 am-5:00 pm EST featuring roundtable discussions with C-suite executives moderated by Maxim Research Analysts, fireside chats with live Q&A, and presentations from hundreds of issuers both domestically and internationally.

180 Life Sciences Corp. to Present at Inaugural Emerging Growth Virtual Conference, presented by M Vest LLC and Maxim Group LLC

MENLO PARK, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the closing of its previously announced private placement of 2,564,000 shares of its common stock and accompanying warrants to purchase an aggregate of up to 2,564,000 shares of common stock at a combined purchase price of $4.55 per share and accompanying warrant. The warrants are exercisable immediately at an exercise price of $5.00 per share and expire five years from the date of issuance. Gross proceeds were approximately $11.7 million, before deducting placement agent fees and other offering expenses. The Company currently intends to use the net proceeds from this offering for general corporate purposes, working capital, and for the research and development of the Company's programs that are not funded by grants.

180 Life Sciences Corp. Announces Closing of $11.7 Million Private Placement

MENLO PARK, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has entered into securities purchase agreements with certain institutional investors to raise approximately $11.7 million through the private placement of 2,564,000 shares of its common stock and accompanying warrants to purchase an aggregate of up to 2,564,000 shares of common stock at a combined purchase price of $4.55 per share and accompanying warrant. The warrants will be exercisable immediately at an exercise price of $5.00 per share and will expire five years from the date of issuance. The closing of the private placement is expected to occur on February 23, 2021, subject to the satisfaction of certain customary closing conditions set forth in the securities purchase agreements.

180 Life Sciences Corp. Announces $11.7 Million Private Placement

Menlo Park, California--(Newsfile Corp. - January 11, 2021) - 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that the Company will present at the Biotech Showcase™ Digital 2021 Conference. The conference is taking place online between January 11-15 and will feature...

180 Life Sciences Corp. to Present at the Biotech Showcase(TM) Digital 2021 Conference

News for 180 Life Sciences Stock (ATNF)